C1 pill
Searched over 200M research papers for "c1 pill"
Summary
3 papers analyzed
These studies suggest that C1 inhibitors are effective in treating hereditary angioedema and reducing renal impairment in severe sepsis, while oral contraceptives can cause angioedema but stopping them can resolve the issue.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Understanding the Role of C1 Inhibitor in Health Conditions
C1 Inhibitor and Oral Contraceptives: Angioedema Risk
Angioedema Triggered by Oral Contraceptives
Oral contraceptives have been linked to the onset of angioedema, a condition characterized by sudden swelling in various parts of the body. Research involving five patients revealed that the use of oral contraceptives could precipitate attacks of hereditary angioedema (HAE) or induce acquired forms of the condition. These patients experienced symptoms such as swelling of the lips, hands, larynx, and abdomen during the first year or later after starting contraception. Notably, all patients had normal serum C4 and C1 inhibitor (C1Inh) antigen levels but showed reduced C1Inh activity, with significant protein cleavage observed on immunoblot tests. Discontinuation of the oral contraceptives led to the regression of edema and normalization of C1Inh function, suggesting a potential modulation of C1Inh expression by androgens or an imbalance in coagulation proteins favoring C1Inh cleavage by its target proteases.
C1 Inhibitor in Severe Sepsis and Septic Shock
Beneficial Effects on Renal Dysfunction
C1 inhibitor has shown promise in treating patients with severe sepsis or septic shock. A double-blind, randomized, placebo-controlled trial involving 40 patients demonstrated that parenteral administration of C1 inhibitor significantly increased plasma C1 inhibitor antigen and activity levels. Patients receiving C1 inhibitor had notably lower serum creatinine concentrations on days 3 and 4 compared to those given a placebo, indicating improved renal function. Additionally, multiple organ dysfunction was less pronounced in the C1 inhibitor group, although the mortality rate remained similar between the two groups. Importantly, no C1 inhibitor-related side effects were reported, highlighting its safety and efficacy in attenuating renal impairment in these critically ill patients.
Prophylaxis of Hereditary Angioedema Attacks
Subcutaneous C1 Inhibitor for HAE Prevention
For patients with hereditary angioedema (HAE), maintaining functional levels of C1 inhibitor activity is crucial for preventing attacks. A study involving patients aged 12 years or older with type 1 or 2 HAE, who experienced four or more attacks in a consecutive two-month period, investigated the efficacy of subcutaneous C1 inhibitor as a prophylactic treatment. This international, prospective, multicenter, randomized, double-blind, placebo-controlled trial demonstrated that subcutaneous administration of C1 inhibitor effectively reduced the frequency of HAE attacks, providing a viable prophylactic option for managing this condition.
Conclusion
C1 inhibitor plays a critical role in managing various health conditions, from preventing angioedema triggered by oral contraceptives to improving renal function in severe sepsis and providing prophylaxis against hereditary angioedema attacks. These findings underscore the importance of C1 inhibitor in clinical settings and its potential to enhance patient outcomes across different medical scenarios.
Sources and full results
Most relevant research papers on this topic
